Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer

Updated review (15 studies; n=11,538) found evidence that supports adding ovarian function suppression for premenopausal women with early, hormone receptor‐positive breast cancers, with benefit persisting vs. observation, and when added to tamoxifen or chemotherapy and tamoxifen.


Cochrane Database of Systematic Reviews